Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 859

The DOI matches its Crossref record.

Clinical Applications of PET in Oncology

Rohren, Eric M., Turkington, Timothy G., Coleman, R. Edward·2004·Radiology
DOI 10.1148/radiol.2312021185
Open this paper in CoChat — free account

Abstract

Positron emission tomography (PET) provides metabolic information that has been documented to be useful in patient care. The properties of positron decay permit accurate imaging of the distribution of positron-emitting radiopharmaceuticals. The wide array of positron-emitting radiopharmaceuticals has been used to characterize multiple physiologic and pathologic states. PET is used for characterizing brain disorders such as Alzheimer disease and epilepsy and cardiac disorders such as coronary artery disease and myocardial viability. The neurologic and cardiac applications of PET are not covered in this review. The major utilization of PET clinically is in oncology and consists of imaging the distribution of fluorine 18 fluorodeoxyglucose (FDG). FDG, an analogue of glucose, accumulates in most tumors in a greater amount than it does in normal tissue. FDG PET is being used in diagnosis and follow-up of several malignancies, and the list of articles supporting its use continues to grow. In this review, the physics and instrumentation aspects of PET are described. Many of the clinical applications in oncology are mature and readily covered by third-party payers. Other applications are being used clinically but have not been as carefully evaluated in the literature, and these applications may not be covered by third-party payers. The developing applications of PET are included in this review.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1148/radiol.2312021185

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 195

  1. Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM.Application of annihilation coincidence detection to transocial reconstruction tomography.J Nucl Med1975; 16:210-214.
  2. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP.Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose.J Nucl Med1978; 19:1154-1161. · DOI
  3. 10.1109/42.363108 · DOI · Paper page
  4. Adam LE, Karp JS, Daube-Witherspoon ME, et al.Performance of a whole-body PET scanner using curve-plate NaI(Tl) detectors.J Nucl Med2001; 42:1821-1830.
  5. Patton JA, Turkington TG.Coincidence imaging with a dual-head scintillation camera.J Nucl Med1999; 40:432-441.
  6. 10.1109/TNS.1986.4337143 · doi:10.1109/tns.1986.4337143
  7. DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE.Performance characteristics of a whole-body PET scanner.J Nucl Med1994; 35:1398-1406.
  8. Brix G, Zaers J, Adam LE, et al.Performance evaluation of a whole-body PET scanner using the NEMA protocol.J Nucl Med1997; 38:1614-1623.
  9. Melcher CL.Scintillation crystals for PET.J Nucl Med2000; 41:1051-1055.
  10. Valk PE, Casey ME, Bruckbauer T, et al.Clinical evaluation of an LSO PET system for 3D whole-body FDG imaging (abstr).J Nucl Med2001; 42:309.
  11. Muehllrhner G, Karp JS, Surti S.Design considerations for PET scanners.Q J Nucl Med2002; 46:16-23.
  12. 10.1016/S0003-4975(97)00568-7 · doi:10.1016/s0003-4975(97)00568-7
  13. Erasmus JJ, Connolly JE, McAdams HP, Roggli VL.Solitary pulmonary nodules.I. Morphologic evaluation for differentiation of benign and malignant lesions. RadioGraphics2000; 20:43-58. · DOI · Paper page
  14. Dholakia S, Rappaport DC.The solitary pulmonary nodule: is it malignant or benign?Postgrad Med1996; 99:246-250.
  15. 10.2214/ajr.168.2.9016198 · doi:10.2214/ajr.168.2.9016198
  16. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL.Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer.J Nucl Med1999; 40:556-565.
  17. 10.1016/S1010-7940(01)00800-4 · doi:10.1016/s1010-7940(01)00800-4
  18. 10.1378/chest.120.6.1791 · doi:10.1378/chest.120.6.1791
  19. Yang SN, Liang JA, Lin FJ, Kwan AS, Kao CH, Shen YY.Differentiating benign and malignant pulmonary lesions with FDG-PET.Anticancer Res2001; 21:4153-4157.
  20. 10.1001/jama.285.7.914 · DOI · Paper page
  21. Lewis PJ, Salama A.Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis.J Nucl Med1994; 35:1647-1649.
  22. 10.1148/radiology.188.2.8327702 · DOI · Paper page
  23. Matthies A, Hickson M, Cuchiara A, Alavi A.Dual time point 18F-FDG PET for the evaluation of pulmonary nodules.J Nucl Med2002; 43:871-875.
  24. Lowe VJ, Fletcher JW, Gobar L, et al.Prospective investigation of positron emission tomography in lung nodules.J Clin Oncol1998; 16:1075-1084. · DOI · Paper page
  25. Higashi K, Ueda Y, Seki H, et al.Fluorine-18-FDG PET imaging is negative in bronchoalveolar lung carcinoma.J Nucl Med1998; 39:1016-1020.
  26. 10.1148/radiol.2232011131 · DOI
  27. 10.2214/ajr.175.1.1750245 · doi:10.2214/ajr.175.1.1750245
  28. 10.2214/ajr.168.2.9016206 · doi:10.2214/ajr.168.2.9016206
  29. Luke WP, Pearson FG, Todd TR, et al.Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung.J Thorac Cardiovasc Surg1986; 91:53-56. · doi:10.1016/s0022-5223(19)38480-6
  30. 10.1007/s002680020015 · doi:10.1007/s002680020015
  31. 10.1378/chest.108.6.1617 · DOI · Paper page
  32. 10.1148/radiology.215.3.r00jn29886 · doi:10.1148/radiology.215.3.r00jn29886
  33. 10.1007/s002590050327 · DOI · Paper page
  34. Magnani P, Carretta A, Rizzo G, et al.FDG/PET and spiral CT image fusion for mediastinal lymph node assessment of non-small cell lung cancer patients.J Cardiovasc Surg (Torino)1999; 40:741-748.
  35. 10.1016/S0003-4975(98)00675-4 · DOI · Paper page
  36. 10.1148/radiology.212.3.r99se21803 · DOI · Paper page
  37. 10.2214/ajr.168.5.9129444 · DOI · Paper page
  38. 10.1148/radiol.2261010920 · doi:10.1148/radiol.2261010920
  39. 10.1148/radiology.186.1.8416584 · doi:10.1148/radiology.186.1.8416584
  40. Ginsberg RJ, Vokes EE, Rosenzweig K.Epidemiology of non-small cell lung cancer.In: DeVita VT, Hellman S, Rosenberg SA, eds.Cancer: principles and practice of oncology.6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2001; 925-927.
  41. 10.1016/S0022-5223(05)80018-2 · DOI · Paper page
  42. Changlai SP, Tsai SC, Chou MC, Ho YJ, Kao CH.Whole body 18F-2-deoxyglucose positron emission tomography to restage non-small cell lung cancer.Oncol Rep2001; 8:337-339. · doi:10.3892/or.8.2.337
  43. 10.1016/0360-3016(94)00622-R · DOI
  44. 10.1148/radiology.206.3.9494497 · DOI · Paper page
  45. Gupta NC, Falk PM, Frank AL, Thorson AM, Frick MP, Bowman B.Pre-operative staging of colorectal carcinoma using positron emission tomography.Nebr Med J1993; 78:30-35.
  46. Skibber JM, Minsky BD, Hoff PM.Spread of colorectal cancer.In: DeVita VT, Hellman S, Rosenberg SA, eds.Cancer: principles and practice of oncology.6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2001; 1229-1230.
  47. 10.1001/archsurg.1984.01390180015003 · doi:10.1001/archsurg.1984.01390180015003
  48. 10.1097/00000658-198502000-00012 · doi:10.1097/00000658-198502000-00012
  49. 10.1002/(SICI)1098-2388(199607/08)12:4<219::AID-SSU3>3.0.CO;2-8 · DOI · Paper page
  50. 10.1016/S0002-9610(99)80067-1 · DOI · Paper page
  51. 10.1007/s004230050255 · DOI
  52. Boykin KN, Zibari GB, Lilien DL, McMillan RW, Aultman DF, McDonald JC.The use of FDG-positron emission tomography for the evaluation of colorectal metastases to the liver.Am Surg1999; 65:1183-1185. · doi:10.1177/000313489906501220
  53. 10.1016/S0002-9610(99)00187-7 · DOI · Paper page
  54. 10.1097/00003072-200208000-00002 · DOI
  55. Huebner RH, Park KC, Shepherd JE, et al.A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer.J Nucl Med2000; 41:1177-1189.
  56. 10.1097/00000658-200103000-00001 · DOI · Paper page
  57. 10.1002/bjs.1800780711 · doi:10.1002/bjs.1800780711
  58. 10.1016/S0002-9610(97)00020-2 · doi:10.1016/s0002-9610(97)00020-2
  59. Hung GU, Shiau YC, Tsai SC, Chao TH, Ho YJ, Kao CH.Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer.Anticancer Res2001; 21:1375-1378.
  60. 10.1046/j.1365-2168.1999.01178.x · DOI
  61. 10.1002/1097-0142(20000901)89:5<1019::AID-CNCR11>3.0.CO;2-0 · doi:10.1002/1097-0142(20000901)89:5<1019::aid-cncr11>3.0.co;2-0
  62. Gershenwald JE, Thompson W, Mansfield PF, et al.Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients.J Clin Oncol1999; 17:976-983. · DOI · Paper page
  63. Reintgen D, Rapaport D, Tanabe KK, Ross M.Lymphatic mapping and sentinel node biopsy in patients with malignant melanoma.J Fla Med Assoc1997; 84:188-193.
  64. 10.1097/00006534-199909020-00010 · doi:10.1097/00006534-199909020-00010
  65. 10.1007/BF02316805 · doi:10.1007/bf02316805
  66. Klein M, Freedman N, Lotem M, et al.Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma: a pilot study.Nuklearmedizin2000; 39:56-61. · doi:10.1055/s-0038-1632245
  67. Wagner JD, Schauwecker D, Davidson D, et al.Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy.J Clin Oncol1999; 17:1508-1515. · DOI · Paper page
  68. 10.1002/1097-0142(20010415)91:8<1530::AID-CNCR1162>3.0.CO;2-# · doi:10.1002/1097-0142(20010415)91:8<1530::aid-cncr1162>3.0.co;2-#
  69. Acland KM, Healy C, Calonje E, et al.Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous melanoma.J Clin Oncol2001; 19:2674-2678. · doi:10.1200/jco.2001.19.10.2674
  70. 10.1002/jso.1102 · DOI
  71. Schwimmer J, Essner R, Patel A, et al.A review of the literature for whole-body FDG PET in the management of patients with melanoma.Q J Nucl Med2000; 44:153-167.
  72. Hoffman JM, Wakin HA, Schifter T, et al.FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS.J Nucl Med1993; 34:567-575.
  73. 10.1097/00004728-199507000-00004 · DOI
  74. 10.1258/0956462961918239 · DOI
  75. O’Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS.PET scanning and the human immunodeficiency virus-positive patient.J Nucl Med1997; 38:1575-1583.
  76. Leskinen-Kallio S, Ruotsalainen U, Nägran K, et al.Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin’s lymphoma: a PET study.J Nucl Med1991; 32:1211-1218.
  77. Rodriguez M, Rehn S, Ahlström H, Sundström C, Glimelius B.Predicting malignancy grade with PET in non-Hodgkin’s lymphoma.J Nucl Med1995; 36:1790-1796.
  78. 10.1023/A:1011169332265 · DOI · Paper page
  79. 10.1023/A:1008312726163 · DOI
  80. 10.1097/00003072-200106000-00014 · DOI
  81. 10.1023/A:1012548312538 · doi:10.1023/a:1012548312538
  82. 10.1097/00003072-200011000-00026 · DOI
  83. 10.1023/A:1011136324038 · doi:10.1023/a:1011136324038
  84. 10.1007/s005860100339 · doi:10.1007/s005860100339
  85. 10.1007/s002590050275 · DOI · Paper page
  86. 10.1148/radiology.203.3.9169707 · DOI · Paper page
  87. Paul R.Comparison of fluorine-18–2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma.J Nucl Med1987; 28:288-292.
  88. 10.1002/cncr.10336 · DOI · Paper page
  89. Moog F, Bangerter M, Kotzerke J, et al.18-F-fluorodeoxyglucose positron emission tomography as a new approach to detect lymphomatous bone marrow.J Clin Oncol1998; 16:603-609. · DOI · Paper page
  90. Carr R, Barrington SF, Madan B, et al.Detection of lymphoma in bone marrow by whole-body positron emission tomography.Blood1998; 91:3340-3346. · DOI · Paper page
  91. Moog F, Kotzerke J, Reske SN.FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma.J Nucl Med1999; 40:1407-1413.
  92. 10.1097/00003072-199802000-00007 · DOI
  93. Sugawara Y, Zasadny KR, Kison PV, Baker LH, Wahl RL.Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results.J Nucl Med1999; 40:1456-1462.
  94. 10.1080/10428199909169622 · doi:10.1080/10428199909169622
  95. 10.1007/BF02796208 · doi:10.1007/bf02796208
  96. 10.1089/cbr.1999.14.251 · doi:10.1089/cbr.1999.14.251
  97. Cremerius U, Fabry U, Neuerburg J, et al.Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.Nuklearmedizin2001; 40:23-30. · DOI
  98. de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK.18FDG-PET following treatment as a valid predictor for disease-free survival in Hodgkin’s lymphoma.Ann Oncol2001; 12:29-37. · doi:10.1023/a:1008357126404
  99. Spaepen K, Stroobants S, Dupont P, et al.Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?J Clin Oncol2001; 19:414-419. · DOI · Paper page
  100. Römer W, Hanauske AR, Ziegler S, et al.Positron emission tomography in non-Hodgkin’s lymphoma: assessment of chemotherapy with fluorodeoxyglucose.Blood1998; 91:4464-4471.
  101. 10.1016/S1040-8428(01)00127-5 · doi:10.1016/s1040-8428(01)00127-5
  102. 10.1016/S1095-0397(99)00035-7 · DOI
  103. 10.1097/00003072-200011000-00005 · DOI
  104. 10.1097/00003072-199912000-00026 · DOI
  105. 10.1067/mtc.2000.110464 · DOI · Paper page
  106. Rice TW, Boyce GA, Sivak MV.Esophageal ultrasound and the preoperative staging of carcinoma of the esophagus.J Thorac Cardiovasc Surg1991; 101:536-543; discussion 543–544. · doi:10.1016/s0022-5223(19)36738-8
  107. Saunders HS, Wolfman NT, Ott DJ.Esophageal cancer: radiologic staging.Radiol Clin North Am1997; 35:281-294. · doi:10.1016/s0033-8389(22)00708-4
  108. 10.1002/1097-0142(19820515)49:10<2173::AID-CNCR2820491032>3.0.CO;2-Z · doi:10.1002/1097-0142(19820515)49:10<2173::aid-cncr2820491032>3.0.co;2-z
  109. 10.1097/00000658-200012000-00003 · DOI · Paper page
  110. 10.1016/S0003-4975(00)02221-9 · doi:10.1016/s0003-4975(00)02221-9
  111. 10.1016/S0003-4975(97)00619-X · DOI · Paper page
  112. 10.1002/cncr.10330 · DOI
  113. 10.1016/S0009-9260(98)80292-4 · DOI
  114. 10.1016/S0003-4975(99)00974-1 · DOI · Paper page
  115. Rice TW.Clinical staging of esophageal carcinoma: CT, EUS, and PET.Chest Surg Clin N Am2000; 10:471-485.
  116. 10.1038/bjc.1998.526 · DOI · Paper page
  117. 10.1016/S0360-3016(97)00025-4 · doi:10.1016/s0360-3016(97)00025-4
  118. 10.1002/(SICI)1097-0347(199812)20:8<674::AID-HED3>3.0.CO;2-H · doi:10.1002/(sici)1097-0347(199812)20:8<674::aid-hed3>3.0.co;2-h
  119. 10.1002/(SICI)1097-0347(199812)20:8<739::AID-HED13>3.0.CO;2-0 · doi:10.1002/(sici)1097-0347(199812)20:8<739::aid-hed13>3.0.co;2-0
  120. 10.1097/00003072-199912000-00009 · DOI
  121. 10.1148/radiology.199.3.8638002 · doi:10.1148/radiology.199.3.8638002
  122. 10.1002/(SICI)1097-0142(19980315)82:6<1160::AID-CNCR22>3.0.CO;2-3 · doi:10.1002/(sici)1097-0142(19980315)82:6<1160::aid-cncr22>3.0.co;2-3
  123. 10.1148/radiology.210.1.r99ja48177 · DOI
  124. 10.1007/s002590100554 · DOI · Paper page
  125. 10.1046/j.1365-2273.1997.00852.x · DOI
  126. Nowak B, Di Martino E, Janicke S, et al.Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI.Nuklearmedizin1999; 38:312-318. · DOI
  127. 10.1001/archotol.126.12.1457 · DOI
  128. 10.1002/hed.1136 · doi:10.1002/hed.1136
  129. 10.1002/hed.2890100304 · doi:10.1002/hed.2890100304
  130. 10.1097/00005537-199905000-00021 · doi:10.1097/00005537-199905000-00021
  131. 10.1007/s002590050293 · DOI · Paper page
  132. Manolidis S, Donald PJ, Volk P, Pounds TR.The use of positron emission tomography scanning in occult and recurrent head and neck cancer.Acta Otolaryngol Suppl1998; 534:1-11. · DOI
  133. Tepperman BS, Fitzpatrick PJ.Second respiratory and upper digestive tract cancer after oral cancer.Lancet1981; 2:547-549. · doi:10.1016/s0140-6736(81)90938-7
  134. 10.1097/00003072-200102000-00008 · DOI
  135. 10.1097/00005537-200009000-00016 · DOI
  136. Lowe VJ, Boyd JH, Dunphy FR, et al.Surveillance for recurrent head and neck cancer using positron emission tomography.J Clin Oncol2000; 18:651-658. · DOI · Paper page
  137. Zimny M, Wildberger JE, Cremerius U, et al.Combined image interpretation of computed tomography and hybrid PET in head and neck cancer.Nuklearmedizin2002; 41:14-21. · doi:10.1055/s-0038-1623998
  138. 10.1159/000055752 · doi:10.1159/000055752
  139. 10.1093/jnci/93.22.1678 · doi:10.1093/jnci/93.22.1678
  140. 10.1148/radiology.179.3.2027989 · DOI · Paper page
  141. 10.1148/radiology.187.3.8497624 · DOI · Paper page
  142. Avril N, Dose J, Janicke F, et al.Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose.J Clin Oncol1996; 14:1848-1857. · DOI · Paper page
  143. 10.1007/BF00834522 · DOI
  144. 10.1097/00004728-199307000-00012 · DOI
  145. Avril N, Rose CA, Schelling M, et al.Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations.J Clin Oncol2000; 18:3495-3502. · DOI · Paper page
  146. Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK.Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.J Nucl Med1998; 39:431-435.
  147. 10.1007/BF02303557 · DOI
  148. 10.1007/BF01249621 · DOI · Paper page
  149. Crippa F, Agresti R, Seregni E, et al.Prospective evaluation of fluorine-18 FDG PET in presurgical staging of the axilla in breast cancer.J Nucl Med1998; 39:4-8.
  150. 10.1259/bjr.72.863.10700822 · DOI
  151. 10.1093/jjco/hye007 · DOI
  152. Bender H, Kirst J, Palmedo H, et al.Value of 18-fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.Anticancer Res1997; 17:1687-1692.
  153. 10.1007/s002680020095 · doi:10.1007/s002680020095
  154. Vranjesevic D, Filmont JE, Meta J, et al.Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients.J Nucl Med2002; 43:325-329.
  155. 10.1097/00000658-200112000-00012 · DOI
  156. 10.1210/jc.84.7.2291 · DOI · Paper page
  157. 10.1007/s004230050116 · DOI
  158. 10.1097/00003072-200103000-00002 · doi:10.1097/00003072-200103000-00002
  159. Davis PW, Perrier ND, Adler L, Levine EA.Incidental thyroid carcinoma identified by positron emission tomography scanning obtained for metastatic evaluation.Am Surg2001; 67:582-584. · doi:10.1177/000313480106700615
  160. 10.1111/j.1572-0241.1999.01544.x · doi:10.1111/j.1572-0241.1999.01544.x
  161. 10.1016/S0168-8278(00)80248-2 · DOI · Paper page
  162. 10.2214/ajr.171.6.9843289 · DOI
  163. 10.1097/00000658-200111000-00014 · DOI
  164. 10.1007/BF02574503 · DOI
  165. 10.1016/S0090-4295(99)00272-1 · DOI
  166. Sugawara Y, Eisbruch A, Kosuda S, Recker BE, Kison PV, Wahl RL.Evaluation of FDG PET in patients with cervical cancer.J Nucl Med1999; 40:1125-1131.
  167. 10.1097/00004728-199109000-00013 · DOI
  168. 10.1159/000100306 · doi:10.1159/000100306
  169. 10.1002/(SICI)1097-0142(19980901)83:5<918::AID-CNCR17>3.0.CO;2-Y · DOI · Paper page
  170. 10.1016/S1010-7940(00)00535-2 · DOI
  171. 10.1007/BF03164996 · doi:10.1007/bf03164996
  172. Minn H, Lapela M, Klemi PJ, et al.Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer.J Nucl Med1997; 38:1907-1911.
  173. 10.1002/(SICI)1097-0142(19970215)79:4<695::AID-CNCR6>3.0.CO;2-D · DOI
  174. 10.1089/hyb.1999.18.87 · DOI
  175. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R.Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.J Clin Oncol1993; 11:2101-2111. · DOI · Paper page
  176. 10.1007/s002590050359 · DOI · Paper page
  177. 10.1097/00000658-200103000-00002 · DOI · Paper page
  178. 10.1016/S0169-5002(97)00086-X · DOI · Paper page
  179. 10.1016/S0169-5002(99)00005-7 · DOI · Paper page
  180. 10.1002/1097-0142(20010815)92:4<886::AID-CNCR1397>3.0.CO;2-V · doi:10.1002/1097-0142(20010815)92:4<886::aid-cncr1397>3.0.co;2-v
  181. 10.1016/S0167-8140(01)00470-4 · DOI · Paper page
  182. 10.1016/S0360-3016(01)01824-7 · DOI · Paper page
  183. Levivier M, Wikier D, Goldman S, et al.Integration of the metabolic data of positron emission tomography in the dosimetry planning of radiosurgery with the gamma knife: early experience with brain tumors—technical note.J Neurosurg2000; 93(suppl 3):233-238. · doi:10.3171/jns.2000.93.supplement_3.0233
  184. 10.1016/S0360-3016(98)00399-X · DOI
  185. 10.1148/radiology.202.2.9015080 · doi:10.1148/radiology.202.2.9015080
  186. Hara T, Kosaka N, Kishi H.PET imaging of prostate cancer using carbon-11-choline.J Nucl Med1998; 39:990-995.
  187. 10.1002/(SICI)1097-0142(19991101)86:9<1638::AID-CNCR4>3.0.CO;2-U · doi:10.1002/(sici)1097-0142(19991101)86:9<1638::aid-cncr4>3.0.co;2-u
  188. DeGrado TR, Baldwin SW, Wang S, et al.Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers.J Nucl Med2001; 42:1805-1814.
  189. Shields AF, Mankoff DA, Link JM, et al.Carbon-11-thymidine and FDG to measure therapy response.J Nucl Med1998; 39:1757-1762.
  190. 10.1007/s101430050018 · DOI
  191. 10.1002/1097-0142(20010915)92:6<1541::AID-CNCR1480>3.0.CO;2-D · doi:10.1002/1097-0142(20010915)92:6<1541::aid-cncr1480>3.0.co;2-d
  192. 10.1007/s00259-001-0690-4 · doi:10.1007/s00259-001-0690-4
  193. Kole AC, Plaat BE, Hoekstra HJ, Vaalburg W, Molenaar WM.FDG and L-[1–11C]-tyrosine imaging of soft-tissue tumors before and after therapy.J Nucl Med1999; 40:381-386.
  194. 10.1007/s002590000344 · doi:10.1007/s002590000344
  195. Oyama N, Akino H, Kanamaru H, et al.11C-acetate PET imaging of prostate cancer.J Nucl Med2002; 43:181- 186.

Cited by

See all 859

Metadata

Authors
Rohren, E. M., Turkington, T. G., & Coleman, R. E.
Venue
Radiology
Publisher
Radiological Society of North America (RSNA)
Published
2004-05
Volume
231
Issue
2
Pages
305-332
ISSN
  • 0033-8419 (ISSN-L)
  • 1527-1315
DOI
10.1148/radiol.2312021185
OpenAlex
W2114514158
Cited by
859
References
0
FWCI
45.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Applications of PET in Oncology. https://app.cochat.ai/papers/10.1148/radiol.2312021185
The paper
Rohren, E. M., Turkington, T. G., & Coleman, R. E. (2004). Clinical Applications of PET in Oncology. Radiology. https://doi.org/10.1148/radiol.2312021185

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.